Alopecia areata (AA) is an extremely common form of nonscarring hair loss, with a calculated lifetime risk of 2%. It affects both sexes and has no racial predilection, and it represents a significant healthcare burden. 1 Despite the high prevalence, there are no evidence-based treatments for AA. 2 Recent research has uncovered new insights into the etiopathogenesis of AA, which opened the door to the development of new treatment options. 3 Lacarrubba and colleagues first described the trichoscopic features of AA in 2004. Since then, numerous studies showed interest in studying the role of trichoscopy in the diagnosis, assessment of disease activity, severity, prognosis, and therapeutic monitoring of AA. 4,5 Treatment by intralesional corticosteroids (ILCs) remains a standard of care in adults with limited patchy AA. 6-8 However, success rates vary, and local cutaneous atrophy and telangiectasia are common adverse effects. 9Platelet-rich plasma (PRP) has gained much ground, in several medical fields including dermatology and plastic surgery, because of its ability to promote wound healing, 10 its skin rejuvenating effects, 11 and its ability to promote hair growth. 12,13